Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Andreone, P.
space
  arrow  Bernardi, M.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Vitamin E for Chronic Hepatitis B

right arrow Pietro Andreone, MD; Annagiulia Gramonzi; and Mauro Bernardi

15 January 1998 | Volume 128 Issue 2 | Pages 156-157


TO THE EDITOR:

Interferon-{alpha} for chronic hepatitis B is often ineffective and is associated with drawbacks, such as prolonged parenteral schedules, high costs, and side effects [1]. Oral vitamin E is an inexpensive antioxidant that can stimulate the immune response and does not induce side effects [2]. We evaluated vitamin E supplementation as therapy for chronic hepatitis B.

Twenty-four patients (12 were positive for hepatitis B e antigen [HBeAg] and 12 were infected by the "e" minus mutant) with elevated serum alanine aminotransferase (ALT) levels and serum hepatitis B virus DNA (Abbott Laboratories, North Chicago, Illinois) were randomly assigned to receive vitamin E, 300 mg twice daily for 3 months (n = 12), or no treatment (n = 12). They were followed monthly for 9 months. Nineteen patients (10 in the vitamin E group and 9 controls) had been unsuccessfully treated with interferon-{alpha}. At study entry, the study groups were similar with respect to demographic, clinical, and laboratory features. Four HBeAb-positive patients discontinued vitamin E therapy because of severe increases in ALT levels (>10-fold the normal upper limit). A similar finding was seen in 2 controls. The biochemical and virologic responses after 3 and 9 months are shown in the (Table 1). Of the 5 patients with complete response, 2 were positive for HBeAb and 3 were positive for HBeAg at study entry. The HBeAg-positive patients seroconverted to HBeAb during the study period, whereas none of the controls seroconverted from HBeAg to HBeAb. Three of 5 patients with complete response had not responded to previous interferon-{alpha} treatment. Treatment with vitamin E had no side effects. These results suggest that vitamin E is a safe and useful treatment for chronic hepatitis B. Although the mechanism through which these results were achieved is unknown, the stimulatory effect of vitamin E on the immune system probably played a major role. Further studies are needed to confirm these data and to evaluate the effects of a possible combination with other antiviral drugs.


View this table:
[in this window]
[in a new window]
 
Table 1. Biochemical and Virologic Outcomes of Vitamin E in Chronic Hepatitis B*

 


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Universita di Bologna; 40138 Bologna, Italy


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Lok AS. Treatment of chronic hepatitis. Br J Virol Hepatol. 1994; 1:105-24.

2. Meydani M. Vitamin E. Lancet. 1995; 345:170-5.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.




This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
S. Sered and P. Nikolaidis
CT Findings of Perirenal Plasmacytoma
Am. J. Roentgenol., September 1, 2003; 181(3): 888 - 888.
[Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Andreone, P.
space
  arrow  Bernardi, M.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online